Faron Pharmaceuticals Oy operates as a clinical stage drug discovery and development company. The company's lead product candidate is Bexmarilimab, a novel anti-Clever-1 humanized antibody that targets a subpopulation of tumor-associated macrophages and converts the highly immunosuppressive M2-like macrophages to a pro-inflammatory state to promote immune activation. It is also developing bexmarilimab for the treatment of hematological and solid tumor cancers; and in combination with care therapies, azacitidine, and other hypomethylating agents in relapsed/refractory myelodysplastic syndromes, acute myeloid leukemia, and chronic myelomonocytic leukemia. In addition, the company develops receptors involved in regulation of immune response in organ damage and bone marrow regeneration. Faron Pharmaceuticals Oy was founded in 2003 and is headquartered in Turku, Finland.
Frequently asked questions
What sector does Faron Pharmaceuticals Oy (4FR) operate in?
Faron Pharmaceuticals Oy belongs to the Other sector and operates in the Biotechnology industry.
What is Faron Pharmaceuticals Oy (4FR) current stock price?
As of the latest data, Faron Pharmaceuticals Oy stock price is €0.36, with a previous close of €0.37. Faron Pharmaceuticals Oy lost -€0.00 in the last trading session, representing a -1.23% loss.
What is Faron Pharmaceuticals Oy (4FR) current market capitalization?
Faron Pharmaceuticals Oy market cap is approximately 73.54 million.
What is Faron Pharmaceuticals Oy (4FR) Earnings Per Share (EPS)?
The trailing EPS is -€0.12.
Does Faron Pharmaceuticals Oy (4FR) pay dividends?
No. Faron Pharmaceuticals Oy does not pay a dividend.
When is Faron Pharmaceuticals Oy (4FR) next earnings report?
Faron Pharmaceuticals Oy is expected to release its next earnings report on December 31, 2026.
What is Faron Pharmaceuticals Oy (4FR) beta (volatility) score?
Faron Pharmaceuticals Oy has a beta of 1.116, meaning its volatility is roughly in line with the market.
